PANACEABIO · Healthcare · Biotechnology
Composite scorecard: 50/100 — Quality 33 · Momentum 90
| Share price | ₹548.85 |
| Market cap | ₹3,348 Cr |
| P/B ratio | 4.3 |
| ROE | -87.6% |
| ROCE | -0.1% |
| Book value | ₹128.44 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹640 Cr | ₹-7 Cr | -1.0% |
| 2025 | ₹559 Cr | ₹-9 Cr | -4.0% |
| 2024 | ₹559 Cr | ₹-2 Cr | -4.0% |
| 2023 | ₹460 Cr | ₹-34 Cr | -21.0% |
| 2022 | ₹661 Cr | ₹1,078 Cr | -2.0% |
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conj